RE-VERSE-AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial
Clinical Trial Grant
Administered By
Medicine, Hematology
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
January 1, 2015
End Date
June 1, 2017
Administered By
Medicine, Hematology
Awarded By
Boehringer Ingelheim Pharmaceuticals, Inc.
Start Date
January 1, 2015
End Date
June 1, 2017